Presented in OpenZone the new annual report Assobiotec-Federchimica and ENEA “Biotechnology companies in Italy. Facts & Figures 2022 “: a snapshot of the sector over the last two years
A living and vital compartment, engine of national innovationwhich has been able to resist the impact of the pandemic crisis in all its areas of application and which has seen the contribution of Italian-controlled biotech R&D companies significantly increase with a turnover that, in this subgroup of companies, registered a + 30% in the black year of the global health emergency.
- Growing sectorcapable of withstanding the pandemic crisis, national innovation engine, devoted to research
- In numbers: almost 800 companies, 13 thousand employees, over 10 billion in turnover
- Pandemic effect: boom in the turnover of companies dedicated to biotech R&D with Italian capital: + 30%. Investments in biotech R&D also grow: + 15%
- The sectors: in the period 2014 – 2021 progressive and continuous growth in the number of biotech companies for industry (+ 29%) and agriculture (+ 34.5%), but the health sector confirms its centrality (48.5 % of total enterprises)
- At the territorial level: Lombardy is the leader in terms of number of companies (27) and turnover (51%). The regions of the South and the North East are growing in industrial biotech
Based on the main data collected, the Italian biotechnology industry is confirmed therefore, a sector with a stable, if not slightly growing, population of companies, characterized by a strong research and development intensity and with peaks of excellence in all sectors of biotechnology application.
The number of businesses, after a slight decline at the end of 2020, less than 1% (overall the decline in businesses was more than double in the same year), in fact, returned to growth in 2021 exceeding the level reached at the end of 2019 with 790 companies.
The growth has affected all areas of application of biotechnology and in particular the companies dedicated to research and development in Italian-controlled biotechnologies, driven by those with a prevalent application in industrial biotechnologies with + 9% of companies between 2019 and 2020. The sector is characterized by reality of small and micro enterprises which represent just over 82% of the total.
As he tells Alessandro PorcuCEO of OpenZone: “We are very happy to have hosted this event and to witness the extraordinary vitality of the biotechnology sector in Italy. OpenZone is an active part of Assobiotec and its Life Sciences ecosystem, representing at the same time a Lombard and national excellence, a scientific campus entirely dedicated to Health. Every day together with the 34 companies that are part of our community, we are committed to finding innovative solutions and therapies to improve the health of many patients thanks to sharing of skills and relationships“.
“Maybe not everyone knows, but biotechnology has been the basis of all responses to the pandemic crisis: From sequencing the virus genome to molecular diagnostics, from vaccines to monoclonal antibodies and antivirals, everything is based on biotech. And today, at the end of the health emergency but facing new, urgent, dramatic needs: sustainable economic growth, diversification and expansion of energy sources, but also the ability to supply raw materials for human and animal nutrition; biotechnology can once again play a crucial role. The country, with the PNRR, has an extraordinary opportunity to restart and cannot afford to make mistakes now. Choose to initiate reforms andinvest the resources of the Next Generation EU on innovation it means leading the country towards a better future and biotech is certainly a technology that, in this perspective, cannot be neglected “, concludes Elena SgaravattiVice President Assobiotec – Federchimica.
#Biotech #engine #Italian #innovation #Technology #Review #Italia